Abstract 2097P
Background
OM is one of the main adverse events during chemotherapy, affecting around 40% of pts; it is characterized by an inflammation and ulceration of the oral mucous membranes that can lead to oral pain, impaired nutritional intake, local or systemic infections and lower quality of life. Only few strategies are available for its prevention and management. FP-based tp can cause OM due to their cytotoxic effect on mucosal cells inducing DNA double strand brakes and ROS production, empowered by TNF-alfa release. In our retrospective monocentric study we evaluated clinical and hematological RFs which could help us to identify early those patients who might benefit the most from a preventive strategy.
Methods
We evaluated incidence, management and possible RFs for OM (such as diabetes, smoke, BMI and blood inflammation markers) on 174 pts treated with a FP-based tp during a typical month in our DH. Statistical analysis has been conducted using Chi-square test and Fisher’s exact test. Pts have been informed about risk of developing OM and we subsequently managed the symptom on the basis of its severity according to CTCAE.
Results
48 pts developed OM. We found a higher OM incidence in smoker pts (60.5% vs 21.4% in non smoker, p<0.0001) and in overweight pts (39.7% vs 24.1% in pts with normal weight, p=0.0381). We also demonstrated a correlation between a higher OM severity and diabetes diagnosis (71% vs 29.8% in non diabetic pts, p=0.0330). No statistically significant correlation emerged between OM incidence/severity and any of the blood values tested (blood cells values, NLR, PLR, creatinine). 20 pts had ≥G2 OM and received local and/or systemic therapies, while 3 pts needed a treatment suspension. Median time to resolution was 28 days. 6 pts still had OM of various severity grade at the time of our analysis.
Conclusions
Smoke and overweight could be RFs for OM incidence of any grade during a FP-based treatment, while a diabetes diagnosis seemed to be related with a higher severity of OM, but not with its incidence. In view of the above, it might be useful to recommend accurate oral hygiene and a preventive strategy in accordance with MASCC guidelines in these subgroups of pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2045P - Patient Reported Outcome Measures (PROMs) capturing therapy adherence of cancer patients: A systematic literature review
Presenter: Luise Richter
Session: Poster session 06
2046P - The importance of communicating bad news in medical education
Presenter: Georgios Goumas
Session: Poster session 06
2047P - Neutrop: A descriptive, observational study for G-CSF prescription in daily practice
Presenter: Florian Scotté
Session: Poster session 06
2048P - Frequency and clinical relevance of drug-drug interactions with oxycodone among patients with cancer
Presenter: Lotte Hulskotte
Session: Poster session 06
2049P - Osimertinib-related muscle cramps as a common adverse event: A real-world data analysis in the post-approval setting
Presenter: Gisele Moreira
Session: Poster session 06
2050P - Integrating ayurveda herbs with standard of care for management of cancer or cancer treatment related anorexia
Presenter: Yogesh Bendale
Session: Poster session 06
2051P - E-PRO within comprehensive companion program for patients undergoing systemic cancer treatment to reduce emergency visits and inpatient admission in a Peruvian institution
Presenter: Patricia Rioja Viera
Session: Poster session 06
2052P - Adverse events in FLOT chemotherapy for locally advanced gastric cancer: An observational study of pre- and post-operative toxicity profiles
Presenter: Camila Oliveira
Session: Poster session 06
2053P - Dehospitalization through outpatient drug release in clinical pharmacy as a strategic cost-minimization action in a public oncology hospital in the Eastern Amazon: A quantitative analysis
Presenter: Kalysta Borges
Session: Poster session 06
2054P - Metastatic cancer patients hospitalized at initial diagnosis: When does rescue systemic therapy make sense? ONIRIS - A national, prospective study
Presenter: Colin Vercueil
Session: Poster session 06